Hamburg
,
Germany
2 - 6 October 2023
59th Annual Meeting European Association for the Study of Diabetes (EASD 2023)
Presentation schedule and materials
The congress symposium is no longer available
Tuesday, 03 October 2023
ORAL PRESENTATION
Efficacy and safety of once-weekly insulin icodec versus once-daily insulin degludec in type 1 diabetes: ONWARDS 6
David Russell-Jones1; Tetsuya Babazono2; Roman Cailleteau3; Susanne Engberg3; Concetta Irace4; Maiken I S Kjaersgaard5; Chantal Mathieu6; Julio Rosenstock7; Vincent Woo8; David C Klonoff9
ORAL PRESENTATION
Once-weekly insulin icodec versus once-daily insulin degludec in insulin-naïve type 2 diabetes ONWARDS 3: a head-to-head, double-blind study
Ildiko Lingvay1; Marisse Asong2; Cyrus Desouza3; Pierre Gourdy4; Soumitra Kar5; André Vianna6; Tina Vilsbøll7,8,9; Siri Vinther2; Yiming Mu10
SHORT ORAL PRESENTATION
Attitudes and beliefs regarding use of time in range among diabetes healthcare professionals: early results from an online survey conducted in Canada, UK and USA
Alice Y. Y. Cheng1; Christophe De Block2; Amitkumar Agrawal3; Gayathri Anil3; John Michael D'Cruz3; Anna Ginovker4
SHORT ORAL PRESENTATION
Improved HbA1c and time in range with once-weekly insulin icodec versus once-daily insulin glargine U100 in insulin-naïve type 2 diabetes: ONWARDS 1
Julio Rosenstock1; Stephen C Bain2; Amoolya Gowda3; Esteban Jodar4; Bo Liang3; Ildiko Lingvay5; Tomoyuki Nishida6; Roberto Trevisan7; Ofri Mosenzon8
SHORT ORAL PRESENTATION
Improved glycaemic control with once-weekly insulin icodec with a dosing guide app vs once-daily basal insulin analogues in insulin‑naïve type 2 diabetes: ONWARDS 5
Harpreet S Bajaj1; Jens Aberle2; Melanie Davies3; Anders Meller Donatsky4; Marie Frederiksen4; Dilek Gogas Yavuz5; Amoolya Gowda4; Ildiko Lingvay6; Bruce Bode7
SHORT ORAL PRESENTATION
Improved patient-reported outcomes with once-weekly insulin icodec with a dosing guide app versus once-daily basal insulin analogues in type 2 diabetes (ONWARDS 5)
Ronald Goldenberg1; Malik Benamar2; Lisbeth Carstensen2; Melanie Davies3; Anders M Donatsky2; Edward Franek4; Monika Kellerer5; William Polonsky6
SHORT ORAL PRESENTATION
Improved treatment satisfaction with once-weekly insulin icodec versus once-daily insulin degludec in basal insulin-treated type 2 diabetes (ONWARDS 2)
William Polonsky1; Malik Benamar2; Lisbeth Carstensen2; Melanie Davies3; Anders M Donatsky2; Edward Franek4; Monika Kellerer5; Ronald Goldenberg6
SHORT ORAL PRESENTATION
CGM-based metrics and CGM-derived hypoglycaemia duration with once-weekly insulin icodec versus once-daily insulin glargine U100 in insulin-naive T2D: ONWARDS 1 post hoc analyses
Richard Bergenstal1; Björg Ásbjörnsdóttir2; Sara Kehlet Watt2; Ildiko Lingvay3; Julia K Mader4; Tomoyuki Nishida5; Julio Rosenstock6
SHORT ORAL PRESENTATION
Once-weekly insulin icodec and hospitalisation: insights from the ONWARDS 1–6 trials
Athena Philis-Tsimikas1; Julie Krogsdahl Bache2; Tanvir Johanning Bari2; Karen Salvesen-Sykes3; Monika Kellerer4
SHORT ORAL PRESENTATION
Once-weekly insulin icodec: pharmacokinetic and pharmacodynamic properties in type 1 diabetes
Ulrike Hövelmann1; Susanne Engberg2; Tim Heise1; Niels R Kristensen2; Lea Nørgreen3; Rasmus Ribel-Madsen2; Eric Zijlstra1; Hanne Haahr2
SHORT ORAL PRESENTATION
CGM in insulin-experienced individuals with type 2 diabetes switched to once-weekly insulin icodec versus once-daily comparators in ONWARDS 2 and 4: post hoc analysis
Björg Ásbjörnsdóttir1; Harpreet S Bajaj2; Christian Laugesen1; Chantal Mathieu3; Athena Philis-Tsimikas4; Ni Wang1; Tadej Battelino5
ORAL PRESENTATION
Benefit of dual therapy with GLP-1 RA and SGLT2i on cardiovascular outcomes in type 2 diabetes
Bochra Zareini1; Thomas Gerds2; Kathrine Kold Sørensen1; Kim Katrine Bjerring Clemmensen3,4; Kajsa Kvist3; Jens-Peter David3; Christian Torp-Pedersen1
ORAL PRESENTATION
Benefit of dual therapy with GLP-1 RA and SGLT2i on renal outcomes in type 2 diabetes
Kim Katrine Bjerring Clemmensen1,2; Bochra Zareini3; Thomas Gerds4; Kathrine Kold Sørensen3; Kajsa Kvist1; Jens-Peter David1; Christian Torp-Pedersen3
Wednesday, 04 October 2023
ORAL PRESENTATION
Change in Fibrosis-4 Index (FIB4) is associated with risk of liver events, cardiovascular events, and all-cause mortality in patients with obesity and/or type 2 diabetes (T2D)
Kamlesh Khunti1; Tina L. Berentzen2; Louise M. Nitze2; Maximilian Jara2; Anders Jensen2; Mette S. Kjær2; Kamal K. Mangla2; Jens M. Tarp2; Quentin Anstee3,4
MATERIALS AVAILABLE
SHORT ORAL PRESENTATION
The effect of various degrees of hepatic impairment on the pharmacokinetic characteristics of once-weekly insulin icodec
Janne R Hingst1; Blanka Cieslarova2; Anders M Donatsky1; Josmin R Joseph3; Niels R Kristensen1; Viera Kupčová4; Hanne Haahr1
SHORT ORAL PRESENTATION
Efficacy and safety of fast-acting insulin aspart versus insulin aspart both in combination with insulin degludec with or without metformin in adults with diabetes
Jin Du1; Guixia Wang2; Guang Wang3; Ming Liu4; Usha K Thamattoor5; Zijian Luan6; Amra Ciric Alibegovic7; Yiming Mu1
SHORT ORAL PRESENTATION
Pharmacokinetic properties of once-weekly insulin icodec in individuals with renal impairment versus normal renal function
Hanne Haahr1; Niels R Kristensen1; Jonas H Larsen2; Frank-Dietrich H Wagner3; Stanislav Ignatenko3
SHORT ORAL PRESENTATION
Do people living with type 1 diabetes use the dosing flexibility of degludec and does this depend on patient characteristics?
Yvonne Winhofer1; Anne Kaas2; Nikoline Nygård Knudsen2; Johannes Handberg Juul Martiny2; Chantal Mathieu3
SHORT ORAL PRESENTATION
Comparative effectiveness of GLP-1 receptor agonists vs SGLT2 inhibitors in patients with type 2 diabetes and moderate chronic kidney disease
Peter Rossing1,2; Paola Fioretto3; Alice Clark4; Anders Boeck Jensen4; Nicolas Belmar Nazal4; Katherine Tuttle5,6
SHORT ORAL PRESENTATION
Adolescents living with obesity in ACTION Teens: unawareness of their obesity affects their perceptions, attitudes and behaviours
Abdullah Bereket1; Louise A. Baur2; Bassam Bin-Abbas3; Walter Chen4; Fernando Fernández-Aranda5; Nayely Garibay Nieto6; Jason C.G. Halford7; Juan Pedro López Siguero8; Claudio Maffeis9; Vicki Mooney10; Cynthia Karenina Osorto11; Ricardo Reynoso12; Young-Jun Rhie13; Martín Toro-Ramos14
SHORT ORAL PRESENTATION
Association between treatment adherence and CGM outcomes in people with diabetes using smart insulin pens in a real-world setting
Thomas Danne1; Niels Væver Hartvig2; Anne Kaas2; Nikoline Nygård Knudsen2; Julia K Mader3
SHORT ORAL PRESENTATION
Similar hypoglycaemia duration with once-weekly icodec versus degludec or glargine U100 in insulin-treated type 2 diabetes: a post hoc CGM analysis from ONWARDS 2 and 4
Tadej Battelino1; Björg Ásbjörnsdóttir2; Lisbeth Carstensen2; Christian Laugesen2; Chantal Mathieu3; Athena Philis-Tsimikas4; Harpreet Singh Bajaj5
ORAL PRESENTATION
Improvement in time in range after smart pen initiation in routine clinical practice
Peter Adolfsson1; Niels Væver Hartvig2; Anne Kaas2; Nikoline Nygård Knudsen2; Julia Mader3
Thursday, 05 October 2023
SHORT ORAL PRESENTATION
Comparative effectiveness of GLP-1 receptor agonists vs DPP-4 inhibitors in patients with type 2 diabetes and moderate/severe chronic kidney disease
Katherine R Tuttle1,2; Paola Fioretto3; Alice Clark4; Anders Boeck Jensen4; Nicolas Belmar Nazal4; Peter Rossing5,6
SHORT ORAL PRESENTATION
Glucagon-like peptide-1 receptor agonist-experienced adults with type 2 diabetes switching to once-weekly semaglutide: post hoc analysis of the real-world SURE programme
Gottfried Rudofsky1; Markus Menzen2; Louis Potier3; Andrei-Mircea Catarig4; Alice Clark4; Prachi Priyadarshini5; Cristina Abreu6
SHORT ORAL PRESENTATION
Clinical outcomes associated with the use of oral semaglutide in an adult population with type 2 diabetes in Canada: a prospective real-world study (PIONEER REAL Canada)
Sonja M. Reichert1; Hanan Amadid2; Uffe C. Braae2; Ryan M. Bradley3; James Kim4; Victoria Soo5; Jean-François Yale6; Akshay Jain7
SHORT ORAL PRESENTATION
Assessment of age in established atherosclerotic disease or high/very high risk among patients with type 2 diabetes across the Middle East and Africa: the PACT-MEA study
Jihad Haddad1; Wael Almahmeed2; Sam Salek3; Hessa Alkandari4; Naji Alamuddin5; Fatheya Alawadi6; Samir H. Assaad-Khalil7; Tarhan Çınar8; Lise Lotte N. Husemoen9; Landman Lombard10; Rayaz A Malik11; Hani Sabbour2; Mary Ngome8; Gourav Yadav8; Subodh Verma12
SHORT ORAL PRESENTATION
Similar weight loss with semaglutide regardless of diabetes and cardiometabolic parameters in individuals with non-alcoholic fatty liver disease (NAFLD)
Michael Roden1; Takeshi Okanoue2; Mads Sundby Palle3; Anne-Sophie Sejling3; Mohamed Tawfik3; Matthew J. Armstrong4
MATERIALS AVAILABLE
SHORT ORAL PRESENTATION
Incidence of stroke and related outcomes in people with type 2 diabetes: a real-world database study in France
Kamel Mohammedi1; Igor Sibon2; Laurent Fauchier3; Nadia Quignot4; Artak Khachatryan5; Tamar Banon6; Raissa Kapnang4; Kazue Kikuchi4; Hongye Ren7; Christine Massien8; Lucile Vigié8; Sara Larsen7
SHORT ORAL PRESENTATION
Safety Profile of Once-Weekly Subcutaneous Semaglutide in a Real-World Adult Population with T2D
Jean-Francois Yale1; Atheline Major-Pedersen2; Andrei-Mircea Catarig3; Rashmi Jain4; Markus Menzen5; Patrick Holmes6
Keywords